Stay updated with breaking news from Analysis From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
05:30 25.07.2021 Interview - Rückversicherer zu Naturkatastrophen: Das größte Problem sind die Hurrikans Gegen Naturkatastrophen wie in Rheinland-Pfalz und NRW versichern sich Erstversicherungen bei sogenannten Rückversicherern – einer der Branchenriesen ist die Munich Re. Im Gespräch mit dem RedaktionsNetzwerk Deutschland gibt der Geophysiker Ernst Rauch ...
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 American Society of … First-Time Data for KEYTRUDA ® (olaparib) ...
Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluat...
Share this article TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/ -- Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent ® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at ...